Crossmark

Real-world use of nintedanib for the treatment of interstitial lung disease with progressive pulmonary fibrosis

Crossref DOI link: https://doi.org/10.1016/j.medcli.2025.107169

Published Print: 2025-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Cabrera César, Eva

López Garcia, Javier

Cano Gamonoso, Miguel Benitez

López Ramirez, Cecilia

Jiménez Rodriguez, Beatriz

Romero Ortiz, Ana Dolores

Palacios Hidalgo, Zulema

Fole Vázquez, David

Guerrero Zamora, Patricia

Mena Vázquez, Natalia

Hidalgo Molina, Antonio

De La Cruz Morón, Inés

Espildora Hernández, Francisco

Cruz Medina, Antonio

Lacarcel Bautista, Celia

Vegas Viñas, Adriana

Velasco Garrido, José Luis
Funding

Funding for this research was provided by:

Boehringer Ingelheim
License Information

Text and Data Mining valid from 2025-12-01

Text and Data Mining valid from 2025-12-01

stm-asf valid from 2025-12-01

stm-asf valid from 2025-12-01

stm-asf valid from 2025-12-01

stm-asf valid from 2025-12-01

stm-asf valid from 2025-12-01
More Information

This article is maintained by: Elsevier

Article Title: Real-world use of nintedanib for the treatment of interstitial lung disease with progressive pulmonary fibrosis

Journal Title: Medicina Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcli.2025.107169

Content Type: article

Copyright: © 2025 Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.